DOCSLIB.ORG

Australian Public Assessment Report for Fomepizole

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Australian Public Assessment Report for Fomepizole Australian Public Assessment Report for Fomepizole Proprietary Product Name: Antizol Sponsor: AFT Pharmaceuticals August 2017 Therapeutic Goods Administration About the Therapeutic Goods Administration (TGA) • The Therapeutic Goods Administration (TGA) is part of the Australian Government Department of Health and is responsible for regulating medicines and medical devices. • The TGA administers the Therapeutic Goods Act 1989 (the Act), applying a risk management approach designed to ensure therapeutic goods supplied in Australia meet acceptable standards of quality, safety and efficacy (performance) when necessary. • The work of the TGA is based on applying scientific and clinical expertise to decision- making, to ensure that the benefits to consumers outweigh any risks associated with the use of medicines and medical devices. • The TGA relies on the public, healthcare professionals and industry to report problems with medicines or medical devices. TGA investigates reports received by it to determine any necessary regulatory action. • To report a problem with a medicine or medical device, please see the information on the TGA website <https://www.tga.gov.au>. About AusPARs • An Australian Public Assessment Report (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission. • AusPARs are prepared and published by the TGA. • An AusPAR is prepared for submissions that relate to new chemical entities, generic medicines, major variations and extensions of indications. • An AusPAR is a static document; it provides information that relates to a submission at a particular point in time. • A new AusPAR will be developed to reflect changes to indications and/or major variations to a prescription medicine subject to evaluation by the TGA. Copyright © Commonwealth of Australia 2017 This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <[email protected]>. AusPAR Antizol Fomepizole AFT Pharmaceuticals PM-2015-02803-1-3 Page 2 of 72 Final 17 August 2017 Therapeutic Goods Administration Contents Common abbreviations _______________________________________________________ 5 I. Introduction to product submission _____________________________________ 7 Submission details ____________________________________________________________________ 7 Product background __________________________________________________________________ 7 Regulatory status _____________________________________________________________________ 9 Product Information__________________________________________________________________ 9 II. Quality findings ___________________________________________________________ 10 Introduction __________________________________________________________________________ 10 Drug substance (active ingredient) ________________________________________________ 10 Drug product _________________________________________________________________________ 10 Quality summary and conclusions _________________________________________________ 11 III. Nonclinical findings _____________________________________________________ 11 Introduction __________________________________________________________________________ 11 Pharmacology ________________________________________________________________________ 12 Pharmacokinetics ____________________________________________________________________ 13 Toxicology ____________________________________________________________________________ 14 Nonclinical summary and conclusions _____________________________________________ 19 Nonclinical conclusion ______________________________________________________________ 21 IV. Clinical findings __________________________________________________________ 21 Introduction __________________________________________________________________________ 21 Pharmacokinetics ____________________________________________________________________ 23 Pharmacodynamics__________________________________________________________________ 25 Dosage selection for the pivotal studies ___________________________________________ 25 Efficacy _______________________________________________________________________________ 26 Safety _________________________________________________________________________________ 29 First round benefit-risk assessment _______________________________________________ 34 First round recommendation regarding authorisation ___________________________ 36 Second round evaluation of clinical data submitted in response to clinical questions _____________________________________________________________________________ 36 Second round benefit-risk assessment ____________________________________________ 36 V. Pharmacovigilance findings ____________________________________________ 37 Risk management plan ______________________________________________________________ 37 VI. Overall conclusion and risk/benefit assessment __________________ 43 Quality ________________________________________________________________________________ 43 Nonclinical ___________________________________________________________________________ 44 AusPAR Antizol Fomepizole AFT Pharmaceuticals PM-2015-02803-1-3 Page 3 of 72 Final 17 August 2017 Therapeutic Goods Administration Clinical ________________________________________________________________________________ 45 Risk management plan ______________________________________________________________ 55 Risk-benefit analysis ________________________________________________________________ 55 Outcome ______________________________________________________________________________ 71 Attachment 1. Product Information ______________________________________ 71 Attachment 2. Extract from the Clinical Evaluation Report __________ 71 AusPAR Antizol Fomepizole AFT Pharmaceuticals PM-2015-02803-1-3 Page 4 of 72 Final 17 August 2017 Therapeutic Goods Administration Common abbreviations Abbreviation Meaning AACT American Academy of Clinical Toxicology ADH aldehyde dehydrogenase AE Adverse event AUC Area under curve APACHE II Acute Physiology and Chronic Health Evaluation II BD Base deficit BP Blood pressure bpm Beats per minute BUN Blood urea nitrogen Cmax Maximum plasma concentration CI Confidence Interval CVVH Continuous-venovenous haemofiltration CVVHD/HDF Continuous veno-venous haemodialysis/ haemodiafiltration DSW Distilled water EAPCCT European Association of Poisons Centres and Clinical Toxicologists ECG Electrocardiogram EEG Electroencephalogram EG Ethylene glycol IHD Intermittent haemodialysis IV Intravenous IQR Inter quartile range GCP Good Clinical Practice 4MP 4-MethylPyrazole (Fomepizole) Kg Kilogram L Litre LLN Lower limit of normal AusPAR Antizol Fomepizole AFT Pharmaceuticals PM-2015-02803-1-3 Page 5 of 72 Final 17 August 2017 Therapeutic Goods Administration Abbreviation Meaning mg Milligram ml Millilitre NS Normal Saline NCC-MERP National Coordinating Council for Medication Error Reporting and Prevention OG Osmolar Gap PK Pharmacokinetic PD Pharmacodynamic SD Standard deviation SE Standard error SEM Standard error of mean ULN Upper limit of normal µmol Micromoles mmol Millimole Vd Volume of distribution Tmax Time to maximum plasma concentration T1/2 Half life AusPAR Antizol Fomepizole AFT Pharmaceuticals PM-2015-02803-1-3 Page 6 of 72 Final 17 August 2017 Therapeutic Goods Administration I. Introduction to product submission Submission details Type of submission: New chemical entity Decision: Approved Date of decision: 25 November 2016 Date of entry onto ARTG 1 December 2016 Active ingredient(s): Fomepizole Product name(s): Antizol Sponsor’s name and address: AFT Pharmaceuticals PO Box 748 North Ryde NSW 1670 Dose form(s): Concentrated injection Strength(s): 1.5 g/ 1.5 mL Container(s): Vials Pack size(s): 1 and 4s Approved therapeutic use: Antizol® (fomepizole) is indicated for the treatment of ethylene glycol or methanol poisoning. (see Dosage and Administration). Route(s) of administration: Intravenous (IV) Dosage: A loading dose of 15 mg/kg should be administered, followed by doses of 10 mg/kg every 12 h for 4 doses, then 15 mg/kg every 12 h thereafter until ethylene glycol or methanol concentrations are undetectable or have been reduced below 20 mg/dL (ethylene glycol 3.22 mmol/L, methanol 6.24 mmol/L), and the patient is asymptomatic with normal pH. All doses should be administered as a slow intravenous infusion over 30 minutes (see Treatment Guidelines). See Attachment 1 (PI) for further details. ARTG number (s): 263913 Product background This AusPAR describes the application by the sponsor to register fomepizole (as Antizol), a new chemical entity for intravenous infusion in patients with methanol or ethylene glycol
Load more

Recommended publications
  • Methanol Interim AEGL Document
    INTERIM 1: 1/2003 INTERIM 2: 2/2005 INTERIM ACUTE EXPOSURE GUIDELINE LEVELS (AEGLs) METHANOL (CAS Reg. No. 67-56-1) For NAS/COT Subcommittee for AEGLs February 2005 METHANOL Interim 2: 2/2005 PREFACE Under the authority of the Federal Advisory Committee Act (FACA) P. L. 92-463 of 1972, the National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances (NAC/AEGL Committee) has been established to identify, review and interpret relevant toxicologic and other scientific data and develop AEGLs for high priority, acutely toxic chemicals. AEGLs represent threshold exposure limits for the general public and are applicable to emergency exposure periods ranging from 10 minutes to 8 hours. AEGL-2 and AEGL-3 levels, and AEGL-1 levels as appropriate, will be developed for each of five exposure periods (10 and 30 minutes, 1 hour, 4 hours, and 8 hours) and will be distinguished by varying degrees of severity of toxic effects. It is believed that the recommended exposure levels are applicable to the general population including infants and children, and other individuals who may be sensitive or susceptible. The three AEGLs have been defined as follows: AEGL-1 is the airborne concentration (expressed as ppm or mg/m;) of a substance above which it is predicted that the general population, including susceptible individuals, could experience notable discomfort, irritation, or certain asymptomatic, non-sensory effects. However, the effects are not disabling and are transient and reversible upon cessation of exposure. AEGL-2 is the airborne concentration (expressed as ppm or mg/m;) of a substance above which it is predicted that the general population, including susceptible individuals, could experience irreversible or other serious, long-lasting adverse health effects, or an impaired ability to escape.
    [Show full text]
  • Guideline on Antidote Availability for Emergency Departments January 2017
    Royal College of Emergency Medicine and National Poisons Information Service Guideline on Antidote Availability for Emergency Departments January 2017 TOXBASE and/or the BNF should be consulted for further advice on doses and indications for antidote administration and, if necessary, the National Poisons Information Service (NPIS) should be telephoned for more patient-specific advice. Contact details for NPIS are available on TOXBASE. Additional drugs that are used in the poisoned patient that are widely available in ED are not listed in the table – in particular it is important to ensure that insulin, benzodiazepines (diazepam and/or lorazepam), glyceryl trinitrate or isosorbide dinitrate and magnesium are immediately available in the ED. The following drugs should be immediately available in the ED or any area where poisoned patients are initially treated. These drugs should be held in a designated storage facility* The stock held should be sufficient to initiate treatment (stocking guidance is in Appendix 1). Drug Indication Acetylcysteine Paracetamol Activated charcoal Many oral poisons Atropine Organophosphorus or carbamate insecticides Bradycardia Calcium chloride Calcium channel blockers Systemic effects of hydrofluoric acid Calcium gluconate Local infiltration for hydrofluoric acid Calcium gluconate gel Hydrofluoric acid Cyanide antidotes Cyanide Dicobalt edetate The choice of antidote depends on the severity of poisoning, certainty of diagnosis and cause Hydroxocobalamin (Cyanokit®) of poisoning/source of cyanide. Sodium nitrite - Dicobalt edetate is the antidote of choice in severe cases when there is a high clinical Sodium thiosulphate suspicion of cyanide poisoning e.g. after cyanide salt exposure. - Hydroxocobalamin (Cyanokit®) should be considered in smoke inhalation victims who have a severe lactic acidosis, are comatose, in cardiac arrest or have significant cardiovascular compromise - Sodium nitrite may be used if dicobalt edetate is not available.
    [Show full text]
  • Methanol: Toxicological Overview
    Methanol Toxicological Overview Key Points Kinetics and metabolism readily absorbed by all routes and distributed in the body water undergoes extensive metabolism, but small quantities are excreted unchanged by the lungs and in the urine Health effects of acute exposure methanol is toxic following ingestion, inhalation or dermal exposure exposure may initially result in CNS depression, followed by an asymptomatic latent period metabolic acidosis and ocular toxicity, which may result in blindness, are subsequent manifestations of toxicity coma and death may occur following substantial exposures long-term effects may include blindness and, following more substantial exposures, permanent damage to the CNS Health effects of chronic exposure long-term inhalation exposure to methanol has resulted in headaches and eye irritation in workers methanol is considered not to be a mutagen or carcinogen in humans methanol is considered not to be a reproductive toxicant in humans PHE publications gateway number: 2014790 Published: August 2015 Compendium of Chemical Hazards: Methanol Summary of Health Effects Methanol may be acutely toxic following inhalation, oral or dermal exposure. Acute methanol toxicity often follows a characteristic series of features; initially central nervous system (CNS) depression and gastrointestinal tract (GI) irritation may be observed. This is typically followed by a latent period of varying duration from 12–24 hours and occasionally up to 48 hours. Subsequently, a severe metabolic acidosis develops with nausea, vomiting and headache. Ocular toxicity ranges from photophobia and misty or blurred vision to markedly reduced visual acuity and complete blindness following high levels of exposure. Ingestion of as little as 4–10 mL of methanol in adults may cause permanent damage.
    [Show full text]
  • RCEM NPIS Antidote Guideline Appx 1
    Royal College of Emergency Medicine and National Poisons Information Service Guideline on Antidote Availability for Emergency Departments (January 2017) Appendix 1. Stock levels & storage recommendations Doses and Clinical Advice on the Administration of Antidotes TOXBASE and/or the BNF should be consulted for further advice on doses and indications for antidote administration. If necessary, the National Poisons Information Service (NPIS) should be telephoned for more patient-specific advice. Contact details for NPIS are available on TOXBASE. Stock Levels The recommended minimum stocking levels (rounded up to full “pack-sizes” where necessary) are based on the amount of antidote required to initiate treatment for an adult patient in the ED and to continue treatment for the first 24 hours. Higher stock levels may be required and individual departments should determine the amount of each antidote they stock based on the epidemiology of poisoning presentations to their department. Additional drugs that are used in the poisoned patient that are widely available in ED are not listed in the table – in particular it is important to ensure that insulin, benzodiazepines (diazepam and/or lorazepam), glyceryl trinitrate or isosorbide mononitrate and magnesium are immediately available in the ED. The following drugs should be immediately available in the ED or any area where poisoned patients are initially treated These drugs should be held in a designated storage facility Recommended stock Drug Indication Presentation Special storage conditions
    [Show full text]
  • Fomepizole for Acetaminophen Toxicity
    Clinical Pharmacology & Toxicology Pearl of the Week Fomepizole for Acetaminophen Toxicity Mechanisms There are two ways that fomepizole works to help prevent hepatotoxicity in APAP overdose. The primary mechanism involves inhibition of CYP450 2E1. o When a toxic amount of APAP is ingested, the pathways that convert it into nontoxic metabolites become overwhelmed. o Thus, more APAP gets converted into NAPQI. o Fomepizole inhibits the 2E1 pathway, thus preventing conversion of APAP into NAPQI. The second mechanism of action is the JNK (“junk”) enzyme. o NAPQI-induced mitochondrial dysfunction leads to formation of reactive oxidant species. This oxidant stress leads to activation of c-jun N-terminal kinase, or JNK, enzyme. o This enzyme translocates to the mitochondria, amplifying oxidant stress, and ultimately resulting in the cessation of ATP production. o Additionally, the JNK enzyme can lead to the rupture of the outer mitochondrial membrane, causing release of intermembrane proteins, which can potentially lead to DNA fragmentation o Interestingly, it is thought that both metabolic acidosis, as well as elevated lactate levels, may be the result of alterations in mitochondrial respiratory function o Fomepizole works by preventing the APAP-induced activation of this enzyme. Role in Acetaminophen poisoning management In cases where fomepizole and NAC were administered together, evidence has shown that the combination has contributed to a decrease in both hepatotoxicity and mortality. Most of the evidence has come from case reports and animal models. Currently, fomepizole is recommended for massive APAP ingestions (as in, ingestions over 500- 600 mg/kg or in cases where 4-hour equivalent acetaminophen concentrations over 5000 umol/L).
    [Show full text]
  • METHANOL 6 (CAS Reg
    1 INTERIM 1: 1/2003 2 INTERIM 2: 2/2005 3 INTERIM ACUTE EXPOSURE GUIDELINE LEVELS 4 (AEGLs) 5 METHANOL 6 (CAS Reg. No. 67-56-1) 7 For 8 NAS/COT Subcommittee for AEGLs 9 February 2005 METHANOL Interim 2: 2/2005 10 PREFACE 11 Under the authority of the Federal Advisory Committee Act (FACA) P. L. 92-463 of 1972, the 12 National Advisory Committee for Acute Exposure Guideline Levels for Hazardous Substances 13 (NAC/AEGL Committee) has been established to identify, review and interpret relevant toxicologic and 14 other scientific data and develop AEGLs for high priority, acutely toxic chemicals. 15 AEGLs represent threshold exposure limits for the general public and are applicable to emergency 16 exposure periods ranging from 10 minutes to 8 hours. AEGL-2 and AEGL-3 levels, and AEGL-1 levels as 17 appropriate, will be developed for each of five exposure periods (10 and 30 minutes, 1 hour, 4 hours, and 18 8 hours) and will be distinguished by varying degrees of severity of toxic effects. It is believed that the 19 recommended exposure levels are applicable to the general population including infants and children, and 20 other individuals who may be sensitive or susceptible. The three AEGLs have been defined as follows: 21 AEGL-1 is the airborne concentration (expressed as ppm or mg/m³) of a substance above which it 22 is predicted that the general population, including susceptible individuals, could experience notable 23 discomfort, irritation, or certain asymptomatic, non-sensory effects. However, the effects are not disabling 24 and are transient and reversible upon cessation of exposure.
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Evaluation of the Fate and Transport of Methanol in the Environment
    EVALUATION OF THE FATE AND TRANSPORT OF METHANOL IN THE ENVIRONMENT Prepared For: American Methanol Institute 800 Connecticut Avenue, NW, Suite 620 Washington, DC 20006 Prepared By: Malcolm Pirnie, Inc. 180 Grand Avenue, Suite 1000 Oakland, California 94612 JANUARY 1999 3522-002 TABLE OF CONTENTS Page EXECUTIVE SUMMARY .............................................................................................ES-1 1.0 BACKGROUND .................................................................................................... 1 1.1 Purpose and Scope of Report........................................................................ 1 1.2 Introduction and History of Use ................................................................... 1 1.3 Methanol Production..................................................................................... 3 1.4 Chemical and Physical Properties................................................................. 4 1.5 Release Scenarios ......................................................................................... 5 1.6 Fate in the Environment ............................................................................... 7 2.0 PARTITIONING OF METHANOL IN THE ENVIRONMENT........................... 9 2.1 Methanol Partitioning Between Environmental Compartments .................. 9 2.2 Air/Water Partitioning.................................................................................. 9 2.3 Soil/Water Partitioning................................................................................
    [Show full text]
  • A Case of Intentional Methanol Ingestion Sarah Gilligan MD, MS, Devin Horton MD Department of Internal Medicine, University of Utah, Salt Lake City
    A Case of Intentional Methanol Ingestion Sarah Gilligan MD, MS, Devin Horton MD Department of Internal Medicine, University of Utah, Salt Lake City To understand the complications and management of • Any methanol ingestion of more than 1 mg/kg may be • Ophtholmalogic manifestations can include methanol toxicity. lethal. mydriasis, retinal edema leading to retinal sheen, afferent pupillary defect, and, most commonly, toxic • Methanol itself is relatively non-toxic, causing only CNS optic neuropathy. depression; the more severe manifestations of methanol History of Present Illness toxicity are related to the breakdown product formic acid • Studies have shown the optimal treatment of toxic or formate. optic neuropathy is high dose solumedrol followed • 41 year old female with depression, seizure disorder, by a prednisone taper. alcohol abuse, and history of multiple suicide attempts • Metabolism of methanol: alcohol dehydrogenase oxidizes presented to the emergency department reporting that methanol to form formaldehyde which is then oxidized to • It is important to assess the mental health of she had ingested anti-freeze and alcohol and inhaled formic acid. Formic acid is oxidized to non-toxic carbon patients treated for methanol ingestion to gasoline in an attempt to commit suicide. dioxide and water by folate dependent reactions. determine intent and risk of additional self-harm. Physical Exam • Initial manifestations of methanol overdose can be mild • Successful treatment of methanol ingestion requires • Normal vital signs confusion and the appearance of intoxication. early recognition and aggressive multifactorial • Mild suprapubic tenderness medical management aimed at decreasing the levels • Laboratory testing classically shows significant metabolic • Slurred speech and inappropriate affect but alert and of methanol and its metabolites and preventing acidosis with extremely high anion gap and high osmolar answer questions long-term end organ damage.
    [Show full text]
  • 'Tis the Season for Antifreeze…And Its Toxicities!
    VETTALK Volume 15, Number 02 American College of Veterinary Pharmacists ‘Tis the Season for Antifreeze…and its Toxicities! Introduction outcomes. As with ethanol and methanol, resembles ethanol (alcohol) intoxication. Antifreeze is known to most as the EG is also metabolized by ADH to form Dogs and cats exhibit vomiting due to GI neon green liquid that goes into our cars glycoaldehyde which is then oxidized to irritation, polydipsia, polyuria, and neu- to lower the freezing point and prevent glycolate, glyoxalate, and oxalate. Gly- rologic signs such as CNS depression, our radiators from locking up in cold colate and oxalate are responsible for stupor, ataxia, knuckling, decreased with- weather. However, to veterinarians and metabolic acidosis and renal damage. drawal or righting reflexes. Polydipsia veterinary pharmacists, it is ethylene gly- This is because ethylene glycol metabo- occurs due to osmotic stimulation of the col, a source of tens of thousands of ani- lites target the kidney and lead to oliguric thirst center, and polyuria occurs due to mal poisonings each year, the majority of or anuric acute renal injury, which in turn an osmotic diuresis. As CNS depression which occur in late fall, winter, and early slows elimination of ethylene glycol mak- increases in severity, dogs and cats drink spring which is why the timing appeared ing toxicity worst. The process of renal less, however the osmotic diuresis contin- suitable for this newsletter. The other failure is primarily due to glycolate- ues and results in severe dehydration. reason for publishing this article now is induced direct damage to tubules, al- Dogs may appear to transiently recover that the antidote for antifreeze poisoning, though tubule obstruction from precipi- from these CNS signs approximately 12 Antizol-Vet®(fomepizole), is on indefi- tated oxalate crystals may contribute as hours after ingestion.
    [Show full text]
  • World Health Organization Model List of Essential Medicines, 21St List, 2019
    World Health Organizatio n Model List of Essential Medicines 21st List 2019 World Health Organizatio n Model List of Essential Medicines 21st List 2019 WHO/MVP/EMP/IAU/2019.06 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
    [Show full text]
  • Methanol Toxicity Outbreak: When Fear of COVID-19 Goes Viral
    PostScript LETTER in several other centres throughout the Patient and public involvement Patients and/or Emerg Med J: first published as 10.1136/emermed-2020-209886 on 15 May 2020. Downloaded from country during this period. the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer Unlike prior outbreaks, the current Methanol toxicity outbreak: to the Methods section for further details. outbreak of methanol poisoning appears Patient consent for publication Not required. when fear of COVID-19 to be due to the belief that consumption of disinfectants and sanitizers, specif- Provenance and peer review Not commissioned; goes viral internally peer reviewed. ically, alcohol, would be beneficial in preventing the COVID-19 infection. This This article is made freely available for use in Dear editor accordance with BMJ’s website terms and conditions is supported by several cases of methanol for the duration of the covid-19 pandemic or until Methanol ingestion can be a highly poisoning in children resulting from a otherwise determined by BMJ. You may use, download lethal poisoning; methanol is metabolised desperate attempt by parents to prevent and print the article for any lawful, non- commercial to formaldehyde and formic acid, which or cure the infection. When facing a purpose (including text and data mining) provided that all copyright notices and trade marks are retained. are extremely toxic to the central nervous serious health threat, refractory to the system and the gastrointestinal tract available remedies, such irrational deci- © Author(s) (or their employer(s)) 2020. No commercial re- use.
    [Show full text]